influenza vaccine (recombinant)

FluBlok is a recombinant hemagglutinin (HA) influenza vaccine developed by Protein Sciences Corporation (acquired by Sanofi in 2017). It is the first influenza vaccine produced using a baculovirus expression system in insect cells (expresSF+ cell line derived from Spodoptera frugiperda), which allows for an egg-free manufacturing process. The vaccine contains purified recombinant HA proteins from influenza virus strains (typically four for the quadrivalent formulation). Each strain is provided at a higher dose (45 μg) compared to the 15 μg found in standard-dose egg-based vaccines. FluBlok is indicated for active immunization for the prevention of seasonal influenza disease in adults 18 years of age and older.

Brand names

FluBlokFlublok Quadrivalent

Other names

Recombinant hemagglutinin influenza vaccinerHA vaccineRecombinant influenza vaccine